{{Rsnum
|rsid=2521984
|Chromosome=17
|position=32946860
|Orientation=minus
|GMAF=0.2608
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene=LOC102724731
|Gene_s=LOC102724731
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 54.0 | 39.8 | 6.2
| HCB | 100.0 | 0.0 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 12.9 | 51.0 | 36.1
| ASW | 29.8 | 42.1 | 28.1
| CHB | 100.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 59.4 | 37.6 | 3.0
| LWK | 21.8 | 50.0 | 28.2
| MEX | 58.6 | 34.5 | 6.9
| MKK | 25.0 | 57.7 | 17.3
| TSI | 56.9 | 35.3 | 7.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2521984
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.29, combined P value= 5.86E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470246
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2521984
|overall_frequency_n=39
|overall_frequency_d=128
|overall_frequency=0.304688
|n_genomes=26
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}